HTDK Provides End-to-End Commercialization Service for the China Launch of STAAR Surgical’s EVO+ ICL (V5)

Recently, STAAR Surgical’s EVO+ ICL (V5) has officially entered the China market. As STAAR Surgical’s commercialization services partner in China, HTDK is providing end-to-end commercial support—including regulatory-compliant distribution, import & export, inventory management, after-sales service, and nationwide supply-chain operations.

Following the launch, EVO+ ICL (V5) is now being introduced across leading ophthalmic groups, including Chaoju Eye Hospital (Baotou), New Vision Zhongxing Eye Hospital (Shanghai & Chengdu), C-MER Eye Hospital (Shenzhen), and He Eye Hospital (Shenyang & Dalian), supporting broader clinical adoption nationwide.

By combining global innovation with local, compliant commercialization infrastructure, HTDK is proud to help bring advanced refractive technologies to patients across China.